Develops mRNA medicines for liver and respiratory rare diseases.
Jun 2026Revenue $29.4M/yrExpenses $132M/yr
No trendCash runway ≈ 2.6 years from Jun 2026
Figures by year
When will Arcturus Therapeutics Holdings be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $29.4M and expenses $132M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $82.0M | $158M | −$76.3M |
| Dec 2024 | $152M | $248M | −$95.7M |
| Dec 2023 | $167M | $245M | −$78.2M |
| Dec 2022 | $206M | $194M | $12.2M |
| Dec 2021 | $12.4M | $215M | −$203M |
| Dec 2020 | $9.54M | $81.1M | −$71.5M |
| Dec 2019 | $20.8M | $46.3M | −$25.5M |
| Dec 2018 | $15.8M | $37.6M | −$21.8M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.